PL2252300T3 - Zastosowanie 2,4-pirymidynodiamin do leczenia miażdżycy - Google Patents

Zastosowanie 2,4-pirymidynodiamin do leczenia miażdżycy

Info

Publication number
PL2252300T3
PL2252300T3 PL09711944T PL09711944T PL2252300T3 PL 2252300 T3 PL2252300 T3 PL 2252300T3 PL 09711944 T PL09711944 T PL 09711944T PL 09711944 T PL09711944 T PL 09711944T PL 2252300 T3 PL2252300 T3 PL 2252300T3
Authority
PL
Poland
Prior art keywords
pyrimidinediamines
atherosclerosis
treatment
Prior art date
Application number
PL09711944T
Other languages
English (en)
Inventor
Esteban Masuda
Jochen Schmitz
Original Assignee
Rigel Pharmaceuticals, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Rigel Pharmaceuticals, Inc. filed Critical Rigel Pharmaceuticals, Inc.
Publication of PL2252300T3 publication Critical patent/PL2252300T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5383—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/662—Phosphorus acids or esters thereof having P—C bonds, e.g. foscarnet, trichlorfon
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Materials For Medical Uses (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
PL09711944T 2008-02-22 2009-02-20 Zastosowanie 2,4-pirymidynodiamin do leczenia miażdżycy PL2252300T3 (pl)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US3090308P 2008-02-22 2008-02-22

Publications (1)

Publication Number Publication Date
PL2252300T3 true PL2252300T3 (pl) 2017-04-28

Family

ID=40559977

Family Applications (1)

Application Number Title Priority Date Filing Date
PL09711944T PL2252300T3 (pl) 2008-02-22 2009-02-20 Zastosowanie 2,4-pirymidynodiamin do leczenia miażdżycy

Country Status (20)

Country Link
US (1) US8530466B2 (pl)
EP (1) EP2252300B1 (pl)
JP (1) JP5586482B2 (pl)
KR (1) KR101614555B1 (pl)
CN (1) CN102014917A (pl)
AU (1) AU2009215430B2 (pl)
BR (1) BRPI0907724B8 (pl)
CA (1) CA2715962C (pl)
CY (1) CY1118655T1 (pl)
DK (1) DK2252300T3 (pl)
ES (1) ES2610880T3 (pl)
HR (1) HRP20170050T1 (pl)
HU (1) HUE030307T2 (pl)
LT (1) LT2252300T (pl)
MX (1) MX2010009159A (pl)
PL (1) PL2252300T3 (pl)
PT (1) PT2252300T (pl)
RU (1) RU2490015C2 (pl)
SI (1) SI2252300T1 (pl)
WO (1) WO2009105675A1 (pl)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11351168B1 (en) 2008-06-27 2022-06-07 Celgene Car Llc 2,4-disubstituted pyrimidines useful as kinase inhibitors
US8338439B2 (en) 2008-06-27 2012-12-25 Celgene Avilomics Research, Inc. 2,4-disubstituted pyrimidines useful as kinase inhibitors
NZ603525A (en) 2008-06-27 2015-02-27 Celgene Avilomics Res Inc Pyrimidine based compound and uses thereof
DK2516434T3 (en) 2009-12-23 2015-08-31 Takeda Pharmaceutical FUSED HETEROAROMATIC PYRROLIDINONS AS SICK INHIBITORS
BR112012029647A2 (pt) 2010-05-21 2016-08-02 Chemilia Ab novos derivados de pirimidinas
CN105566229A (zh) 2010-08-10 2016-05-11 西建阿维拉米斯研究公司 Btk抑制剂的苯磺酸盐及其用途和制备方法
US9238629B2 (en) 2010-11-01 2016-01-19 Celgene Avilomics Research, Inc. Heteroaryl compounds and uses thereof
SG10201508958WA (en) 2010-11-01 2015-11-27 Celgene Avilomics Res Inc Heterocyclic Compounds And Uses Thereof
EP2637502B1 (en) 2010-11-10 2018-01-10 Celgene CAR LLC Mutant-selective egfr inhibitors and uses thereof
JP5886411B2 (ja) 2011-03-24 2016-03-16 ノビガ・リサーチ・エービーＮｏｖｉｇａ Ｒｅｓｅａｒｃｈ ＡＢ 新規のピリミジン誘導体
WO2012177714A1 (en) 2011-06-22 2012-12-27 Takeda Pharmaceutical Company Limited Substituted 6-aza-isoindolin-1-one derivatives
KR102024120B1 (ko) 2011-07-28 2019-09-23 리겔 파마슈티칼스, 인크. 신규한 (트리메톡시페닐아미노)피리미디닐 제형
JP2014532658A (ja) 2011-10-28 2014-12-08 セルジーン アヴィロミクス リサーチ， インコーポレイテッド ブルトン型チロシンキナーゼ疾患または障害を治療する方法
JP6317319B2 (ja) 2012-03-15 2018-04-25 セルジーン シーエーアール エルエルシー 上皮成長因子受容体キナーゼ阻害剤の固体形態
CA2866857C (en) 2012-03-15 2021-03-09 Celgene Avilomics Research, Inc. Salts of an epidermal growth factor receptor kinase inhibitor
EP2935226A4 (en) 2012-12-21 2016-11-02 Celgene Avilomics Res Inc HETEROARYL COMPOUNDS AND USES THEREOF
US9561228B2 (en) 2013-02-08 2017-02-07 Celgene Avilomics Research, Inc. ERK inhibitors and uses thereof
US9492471B2 (en) 2013-08-27 2016-11-15 Celgene Avilomics Research, Inc. Methods of treating a disease or disorder associated with Bruton'S Tyrosine Kinase
US9415049B2 (en) 2013-12-20 2016-08-16 Celgene Avilomics Research, Inc. Heteroaryl compounds and uses thereof
JP7118642B2 (ja) * 2014-08-08 2022-08-16 アリ リサーチ ソシエタ ア レスポンサビリタ リミタータ センプリフィカタ 炎症性およびアレルギー性病変の治療に用いるための脂肪酸とパルミトイルエタノールアミドの混合物
US10005760B2 (en) 2014-08-13 2018-06-26 Celgene Car Llc Forms and compositions of an ERK inhibitor
WO2020113077A1 (en) 2018-11-29 2020-06-04 The Research Foundation For The State University Of New York Compositions and methods for modular control of bioorthogonal ligation

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5728708A (en) * 1993-10-01 1998-03-17 Novartis Corporation Pharmacologically active pyridine derivatives and processes for the preparation thereof
JP3398152B2 (ja) * 1993-10-12 2003-04-21 ブリストル‐マイヤーズ・スクイブ・ファーマ・カンパニー １ｎ−アルキル−ｎ−アリールピリミジンアミンおよびその誘導体
DE69933680T2 (de) * 1998-08-29 2007-08-23 Astrazeneca Ab Pyrimidine verbindungen
GB9828511D0 (en) * 1998-12-24 1999-02-17 Zeneca Ltd Chemical compounds
CA2451128A1 (en) * 2001-06-26 2003-01-09 Bristol-Myers Squibb Company N-heterocyclic inhibitors of tnf-alpha expression
MXPA04007196A (es) * 2002-01-23 2005-06-08 Bayer Pharmaceuticals Corp Inhibidores de rho-quinasa.
US7288547B2 (en) 2002-03-11 2007-10-30 Schering Ag CDK-inhibitory 2-heteroaryl-pyrimidines, their production and use as pharmaceutical agents
EP1483260A1 (de) 2002-03-11 2004-12-08 Schering Aktiengesellschaft Cdk inhibitorische 2-heteroaryl-pyrimidine, deren herstellung und verwendung als arzneimittel
GB0321710D0 (en) 2003-09-16 2003-10-15 Novartis Ag Organic compounds
TW200517057A (en) * 2003-09-22 2005-06-01 Basf Ag Fungicidal mixtures
EP1796679A1 (en) * 2004-09-10 2007-06-20 Altana Pharma AG Ciclesonide and syk inhibitor combination and methods of use thereof
JP4801096B2 (ja) * 2005-01-19 2011-10-26 ライジェル ファーマシューティカルズ， インコーポレイテッド ２，４−ピリミジンジアミン化合物のプロドラッグおよびそれらの使用
DE102005016634A1 (de) * 2005-04-12 2006-10-19 Merck Patent Gmbh Neuartige Aza-Hetercyclen als Kinase-Inhibitoren
WO2007008541A2 (en) * 2005-07-08 2007-01-18 Kalypsys, Inc. Cellular cholesterol absorption modifiers
US7528143B2 (en) * 2005-11-01 2009-05-05 Targegen, Inc. Bi-aryl meta-pyrimidine inhibitors of kinases
KR20090023698A (ko) 2006-06-15 2009-03-05 베링거 인겔하임 인터내셔날 게엠베하 2-아닐리노-4-아미노알킬렌아미노피리미딘
EP2043651A2 (en) 2006-07-05 2009-04-08 Exelixis, Inc. Methods of using igf1r and abl kinase modulators
CN101903357A (zh) * 2007-07-17 2010-12-01 里格尔药品股份有限公司 作为pkc抑制剂的环状胺取代的嘧啶二胺

Also Published As

Publication number Publication date
AU2009215430A1 (en) 2009-08-27
KR20100126422A (ko) 2010-12-01
JP5586482B2 (ja) 2014-09-10
RU2010138899A (ru) 2012-03-27
JP2011513230A (ja) 2011-04-28
DK2252300T3 (en) 2017-02-06
ES2610880T3 (es) 2017-05-03
HUE030307T2 (en) 2017-04-28
US20110046126A1 (en) 2011-02-24
CN102014917A (zh) 2011-04-13
HRP20170050T1 (hr) 2017-03-10
WO2009105675A1 (en) 2009-08-27
CY1118655T1 (el) 2017-07-12
BRPI0907724A2 (pt) 2017-06-13
HK1150555A1 (en) 2012-01-06
EP2252300B1 (en) 2016-10-19
RU2490015C2 (ru) 2013-08-20
PT2252300T (pt) 2017-01-06
LT2252300T (lt) 2017-02-10
EP2252300A1 (en) 2010-11-24
MX2010009159A (es) 2010-09-14
AU2009215430B2 (en) 2015-02-12
CA2715962C (en) 2017-03-07
SI2252300T1 (sl) 2017-04-26
BRPI0907724B1 (pt) 2019-12-17
BRPI0907724B8 (pt) 2021-05-25
KR101614555B1 (ko) 2016-04-21
CA2715962A1 (en) 2009-08-27
US8530466B2 (en) 2013-09-10

Similar Documents

Publication Publication Date Title
SI2252300T1 (sl) Uporaba 2,4-pirimidindiaminov za zdravljenje ateroskleroze
SI2346864T1 (sl) Nove spojine, uporabne za zdravljenje degenerativnih in vnetnih bolezni
ZA200902374B (en) Compositions useful for the treatment of diabetes
IL200796A0 (en) Device for the treatment of laundry using biocides
ZA201001264B (en) 1-amino-alkylcycohxane derivatives for the treatment of cochleat tinnitus
GB0711342D0 (en) Well treatment
IL205137A0 (en) 5-cyanothienopyridines for the treatment of tumours
GB0800145D0 (en) Skincare treatment
IL210290A0 (en) Use of pyrimidylaminobenzamide derivatives for the treatment of fibrosis
PL2190451T3 (pl) Leczenie miażdżycy
GB0715790D0 (en) Drug combination for the treatment of sialorrhoea
ZA201007362B (en) Conjugates for the treatment of mesothelioma
EP2174956A4 (en) COMPOSITIONS FOR ANTIFIBRINOLYSIS THERAPY
ZA201005306B (en) 5-o-substituted 3-n-phenyl-1,3,4-oxadiazolones for medical use
GB0716784D0 (en) Well treatment
IL207668A0 (en) Beloxepin, its enantiomers, and analogs thereof for the treatment of pain
PL2252302T3 (pl) Kompozycja do leczenia zapalenia kości i stawów
EP2328577A4 (en) TREATMENT OF LOSS OF HEARING
GB0602857D0 (en) The treatment of sialorrhoea
GB0703491D0 (en) The treatment of hyperhidrosis
GB0703492D0 (en) The treatment of hyperhidrosis
GB0809319D0 (en) The treatment of puritus
GB0821381D0 (en) Compositions for the treatment of dry eye
GB0602858D0 (en) The treatment of sialorrhoea
GB0602855D0 (en) The Treatment Of Sialorrhoea